These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 28767562)

  • 21. High Concordance and Negative Prognostic Impact of RAS/BRAF/PIK3CA Mutations in Multiple Resected Colorectal Liver Metastases.
    Brunsell TH; Sveen A; Bjørnbeth BA; Røsok BI; Danielsen SA; Brudvik KW; Berg KCG; Johannessen B; Cengija V; Abildgaard A; Guren MG; Nesbakken A; Lothe RA
    Clin Colorectal Cancer; 2020 Mar; 19(1):e26-e47. PubMed ID: 31982351
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.
    Kleist B; Kempa M; Novy M; Oberkanins C; Xu L; Li G; Loland C; Poetsch M
    Int J Clin Exp Pathol; 2014; 7(9):5927-39. PubMed ID: 25337237
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.
    Passot G; Chun YS; Kopetz SE; Overman MJ; Conrad C; Aloia TA; Vauthey JN
    Eur J Surg Oncol; 2016 Sep; 42(9):1378-84. PubMed ID: 27358198
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RAS Mutation Predicts Positive Resection Margins and Narrower Resection Margins in Patients Undergoing Resection of Colorectal Liver Metastases.
    Brudvik KW; Mise Y; Chung MH; Chun YS; Kopetz SE; Passot G; Conrad C; Maru DM; Aloia TA; Vauthey JN
    Ann Surg Oncol; 2016 Aug; 23(8):2635-43. PubMed ID: 27016292
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-EGF Receptor-Based Conversion Chemotherapy in RAS Wild-Type Colorectal Cancer Patients: Impact on Survival and Resection Rates.
    Koch C; Schmidt N; Winkelmann R; Eichler K; Pession U; Bechstein WO; Zeuzem S; Waidmann O; Trojan J
    Digestion; 2018; 98(4):263-269. PubMed ID: 30130797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases.
    Karagkounis G; Torbenson MS; Daniel HD; Azad NS; Diaz LA; Donehower RC; Hirose K; Ahuja N; Pawlik TM; Choti MA
    Cancer; 2013 Dec; 119(23):4137-44. PubMed ID: 24104864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Codon 13 KRAS mutation predicts patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases.
    Margonis GA; Kim Y; Sasaki K; Samaha M; Amini N; Pawlik TM
    Cancer; 2016 Sep; 122(17):2698-707. PubMed ID: 27244540
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update.
    O Connor JM; Sanchez Loria F; Ardiles V; Grondona J; Sanchez P; Andriani O; Fauda M; Brancato F; Huertas E; Alvarez F; de Santibañes E
    Future Oncol; 2019 Sep; 15(27):3149-3157. PubMed ID: 31426677
    [No Abstract]   [Full Text] [Related]  

  • 29. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.
    Passiglia F; Bronte G; Bazan V; Galvano A; Vincenzi B; Russo A
    Crit Rev Oncol Hematol; 2016 Mar; 99():150-7. PubMed ID: 26775732
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and coexistence of KRAS, BRAF, PIK3CA, NRAS, TP53, and APC mutations in Indian colorectal cancer patients: Next-generation sequencing-based cohort study.
    Jauhri M; Bhatnagar A; Gupta S; Bp M; Minhas S; Shokeen Y; Aggarwal S
    Tumour Biol; 2017 Feb; 39(2):1010428317692265. PubMed ID: 28222664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion.
    Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N
    Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interactions of multiple gene alterations in colorectal liver metastases.
    Kawaguchi Y; Velasco JD; Arvide EM; Wei SH; Vauthey JN
    Chin Clin Oncol; 2019 Oct; 8(5):50. PubMed ID: 31500427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Prognostic Impact of KRAS Mutation in Patients Having Curative Resection of Synchronous Colorectal Liver Metastases.
    Goffredo P; Utria AF; Beck AC; Chun YS; Howe JR; Weigel RJ; Vauthey JN; Hassan I
    J Gastrointest Surg; 2019 Oct; 23(10):1957-1963. PubMed ID: 30276588
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preliminary Analysis of Liquid Biopsy after Hepatectomy for Colorectal Liver Metastases.
    Mason MC; Tzeng CD; Tran Cao HS; Aloia TA; Newhook TE; Overman MJ; Kopetz SE; Vauthey JN; Chun YS
    J Am Coll Surg; 2021 Jul; 233(1):82-89.e1. PubMed ID: 33667566
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene mutation and surgical technique: Suggestion or more?
    Kawaguchi Y; Lillemoe HA; Vauthey JN
    Surg Oncol; 2020 Jun; 33():210-215. PubMed ID: 31351766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neither Surgical Margin Status nor Somatic Mutation Predicts Local Recurrence After R0-intent Resection for Colorectal Liver Metastases.
    Nishioka Y; Paez-Arango N; Boettcher FO; Kawaguchi Y; Newhook TE; Chun YS; Tzeng CD; Tran Cao HS; Lee JE; Vreeland TJ; Vauthey JN
    J Gastrointest Surg; 2022 Apr; 26(4):791-801. PubMed ID: 34725784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy.
    Sebagh M; Allard MA; Bosselut N; Dao M; Vibert E; Lewin M; Lemoine A; Cherqui D; Adam R; Sa Cunha A
    Oncotarget; 2016 Apr; 7(16):21591-600. PubMed ID: 26943031
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comprehensive Complication Index Predicts Cancer-specific Survival After Resection of Colorectal Metastases Independent of RAS Mutational Status.
    Yamashita S; Sheth RA; Niekamp AS; Aloia TA; Chun YS; Lee JE; Vauthey JN; Conrad C
    Ann Surg; 2017 Dec; 266(6):1045-1054. PubMed ID: 27735824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.